FI3638277T3 - Koostumukset ja menetelmät beetasekretaasin estämiseksi - Google Patents
Koostumukset ja menetelmät beetasekretaasin estämiseksi Download PDFInfo
- Publication number
- FI3638277T3 FI3638277T3 FIEP18816475.0T FI18816475T FI3638277T3 FI 3638277 T3 FI3638277 T3 FI 3638277T3 FI 18816475 T FI18816475 T FI 18816475T FI 3638277 T3 FI3638277 T3 FI 3638277T3
- Authority
- FI
- Finland
- Prior art keywords
- weight
- composition
- oroxylin
- chrysin
- baicalein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Confectionery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520141P | 2017-06-15 | 2017-06-15 | |
| PCT/US2018/037454 WO2018232063A1 (en) | 2017-06-15 | 2018-06-14 | Compositions and methods for beta secretase inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3638277T3 true FI3638277T3 (fi) | 2025-01-10 |
Family
ID=64655980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18816475.0T FI3638277T3 (fi) | 2017-06-15 | 2018-06-14 | Koostumukset ja menetelmät beetasekretaasin estämiseksi |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11458117B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3638277B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7209645B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20190134809A (cg-RX-API-DMAC10.html) |
| CA (2) | CA3063751C (cg-RX-API-DMAC10.html) |
| ES (1) | ES3005508T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI3638277T3 (cg-RX-API-DMAC10.html) |
| PL (2) | PL3638277T3 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2018232063A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3638277T3 (pl) * | 2017-06-15 | 2025-03-10 | Sami Labs Limited | Kompozycje i sposoby hamowania beta sekretazy |
| US12465585B2 (en) * | 2018-06-15 | 2025-11-11 | Sami-Sabinsa Group Limited | Compositions for the management of seizure induced neurotoxicity |
| CN110115712A (zh) * | 2019-07-04 | 2019-08-13 | 兰州大学 | 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用 |
| EP4021397A4 (en) * | 2019-08-26 | 2023-09-27 | Sami-Sabinsa Group Limited | HERBAL ACTIVE INGREDIENTS AND THEIR EFFECT AGAINST POLLUTION |
| CN114246879B (zh) * | 2021-12-30 | 2023-10-27 | 沈阳兴齐眼药股份有限公司 | 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945518B2 (en) * | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
| CA2703698C (en) * | 2002-04-30 | 2016-11-22 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| US8034387B2 (en) * | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| NZ545565A (en) * | 2003-09-02 | 2009-06-26 | Unigen Pharmaceuticals Inc | Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| KR20080091436A (ko) * | 2006-01-09 | 2008-10-13 | 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 | 위장관 독성, 관련 증상 및 궤양 치료용 천연물질 |
| EP1986670B1 (en) * | 2006-02-21 | 2017-06-28 | Council of Scientific and Industrial Research | Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof |
| US20100029654A1 (en) * | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| KR20080008929A (ko) * | 2006-11-20 | 2008-01-24 | 대한민국(관리부서 식품의약품 안전청장) | 오록실린 ａ를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품 |
| EP2890391A4 (en) * | 2012-08-29 | 2016-03-09 | Mannkind Corp | METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA |
| CA3043168C (en) * | 2016-11-11 | 2021-05-18 | Sami Labs Limited | Composition containing oroxylin a and method of extraction thereof |
| PL3638277T3 (pl) * | 2017-06-15 | 2025-03-10 | Sami Labs Limited | Kompozycje i sposoby hamowania beta sekretazy |
-
2018
- 2018-06-14 PL PL18816475.0T patent/PL3638277T3/pl unknown
- 2018-06-14 KR KR1020197034396A patent/KR20190134809A/ko not_active Ceased
- 2018-06-14 FI FIEP18816475.0T patent/FI3638277T3/fi active
- 2018-06-14 JP JP2019568236A patent/JP7209645B2/ja active Active
- 2018-06-14 CA CA3063751A patent/CA3063751C/en active Active
- 2018-06-14 WO PCT/US2018/037454 patent/WO2018232063A1/en not_active Ceased
- 2018-06-14 ES ES18816475T patent/ES3005508T3/es active Active
- 2018-06-14 EP EP18816475.0A patent/EP3638277B1/en active Active
- 2018-06-14 US US16/008,219 patent/US11458117B2/en active Active
- 2018-06-15 CA CA3063757A patent/CA3063757C/en active Active
- 2018-06-15 WO PCT/US2018/037724 patent/WO2018232224A1/en not_active Ceased
- 2018-06-15 US US16/009,490 patent/US10894029B2/en active Active
- 2018-06-15 PL PL18817403.1T patent/PL3638278T3/pl unknown
- 2018-06-15 JP JP2019569247A patent/JP6796217B2/ja active Active
- 2018-06-15 KR KR1020197033007A patent/KR20190131589A/ko not_active Ceased
- 2018-06-15 EP EP18817403.1A patent/EP3638278B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7209645B2 (ja) | 2023-01-20 |
| US20180360800A1 (en) | 2018-12-20 |
| JP2020523372A (ja) | 2020-08-06 |
| EP3638277A4 (en) | 2021-03-17 |
| CA3063757A1 (en) | 2018-12-20 |
| JP6796217B2 (ja) | 2020-12-02 |
| US11458117B2 (en) | 2022-10-04 |
| US10894029B2 (en) | 2021-01-19 |
| CA3063751A1 (en) | 2018-12-20 |
| EP3638277B1 (en) | 2024-10-09 |
| CA3063751C (en) | 2023-01-03 |
| PL3638278T3 (pl) | 2022-10-03 |
| EP3638278A4 (en) | 2021-03-17 |
| KR20190131589A (ko) | 2019-11-26 |
| WO2018232063A1 (en) | 2018-12-20 |
| PL3638277T3 (pl) | 2025-03-10 |
| US20180360801A1 (en) | 2018-12-20 |
| EP3638278B1 (en) | 2022-05-11 |
| ES3005508T3 (en) | 2025-03-14 |
| KR20190134809A (ko) | 2019-12-04 |
| EP3638277A1 (en) | 2020-04-22 |
| WO2018232224A1 (en) | 2018-12-20 |
| EP3638278A1 (en) | 2020-04-22 |
| JP2020523342A (ja) | 2020-08-06 |
| CA3063757C (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023251426B2 (en) | Combinations of cannabinoids and N-acylethanolamines | |
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| JP2023503071A5 (cg-RX-API-DMAC10.html) | ||
| MX2022007276A (es) | Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas. | |
| NO20063693L (no) | Forbindelse og metode for anvendelse | |
| PH12012502079A1 (en) | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
| CO2022000657A2 (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
| JP2020523342A5 (cg-RX-API-DMAC10.html) | ||
| WO2019205748A1 (zh) | 一种化合物在抑制A β蛋白聚积治疗老年痴呆方面的应用 | |
| MX2022005843A (es) | Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5). | |
| CN104523679A (zh) | 青蒿琥酯在制备治疗、预防中枢神经损伤药物中的应用 | |
| Li et al. | Atorvastatin calcium ameliorates cognitive deficits through the AMPK/Mtor pathway in rats with vascular dementia | |
| MX2025012741A (es) | Composiciones farmaceuticas orales | |
| CN105030807B (zh) | 烟酰胺核糖在制备治疗脑缺血疾病药物中的应用 | |
| WO2025008516A3 (en) | Indole derivatives with factor b inhibitory activity | |
| WO2011061554A8 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| NO20090814L (no) | N-fenyl-prenylamin derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser | |
| CN104224808B (zh) | 米诺环素用于妊娠期间应激所致的后代神经精神损伤的保护作用 | |
| US9333207B2 (en) | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cerebrovascular disease and neurodegenerative diseases of the central nervous system | |
| CN107648209A (zh) | 一种化合物在改善认知记忆能力和减少老年斑方面的应用 | |
| GB2306321A (en) | The use of (+)-catechin in the treatment or prophylaxis of connective tissue disorders | |
| RU2017135273A (ru) | Пирролидон-карбоновая кислота (рса) для офтальмологического применения | |
| HK40085288A (en) | Combinations of cannabinoids and n-acylethanolamines | |
| EP3212195A1 (en) | Compositions and methods for treating hiv-associated cognitive dysfunction | |
| Mehdizadeh et al. | The beneficial effect of the flavonoid quercetin on behavioral changes in hemi-Parkinsonian rats |